RxDoctor Payments Data

Duane Bridges, MD

Clinical Cardiac Electrophysiology · Inglewood, CANPI 1154352011

Payments from drug & device makers

$67,871in general payments, 2019–2025

Across 575 payments — averaging $118.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$45K
  • Medtronic$11K
  • Boston Scientific$6K
  • Abbott$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$769
  • E.r. Squibb & Sons, L.L.C.$758
  • plus $3K from 21 others

What the payments were for

  • Speaking & faculty fees$8,00016%
  • Travel & lodging$25,85550%
  • Food & beverage$17,48634%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,871 in reported general payments places this provider in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$292,201
Medicare patients
392
Services billed
2,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$177,458
EntrestoSacubitril/Valsartan66$71,814
MultaqDronedarone Hcl43$65,550
XareltoRivaroxaban33$30,877
JardianceEmpagliflozin12$11,939
VerquvoVericiguat12$8,461
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine12$4,397
Diltiazem 12hr ErDiltiazem Hcl14$2,305
Mexiletine Hcl20$1,961
Flecainide Acetate42$1,908
Potassium Chloride32$1,127
Amiodarone Hcl54$919
SotalolSotalol Hcl51$915
Carvedilol61$521
Atorvastatin Calcium64$368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$182$177,458166 claims
NovartisEntresto$43$71,81466 claims
Sanofi-aventis U.S. LLCMultaq$653$65,55043 claims
Johnson & JohnsonXarelto$20$30,87733 claims
Boehringer IngelheimJardiance$41$11,93912 claims
MerckVerquvo$162$8,46112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Inglewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →